Iatrogenic myelomonocytic leukemia following melphalan treatment of scleromyxedema

F. Helm, T. N. Helm

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

We report the case of a patient with scleromyxedema with abnormal monoclonal gammaglobulin of the kappa type who was treated with melphalan (Alkeran®), an alkylating agent. After nine and one-half years of therapy, the patient showed myelomonocytic leukemia. The risk of secondary malignancies must be considered when weighing the benefits and risks of melphalan treatment.

Original languageEnglish (US)
Pages (from-to)219-223
Number of pages5
JournalCutis
Volume39
Issue number3
StatePublished - 1987

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this